Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIOFQE)

• Drug Name: SOMATOSTATIN Drug Info
• Synonyms: 51110-01-1; Somiaton; Panhibin; Aminopan; Somatostatin acetate; SRIF; Somatotropin release-inhibiting factor; Somatotropin release-inhibiting hormone; Growth hormone release-inhibiting factor; CCRIS 7071; EINECS 256-969-7; Growth hormone release-inhibiting hormone; AY 24910; Growth hormone release inhibiting factor; Somatostatin 1-14; Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys; NCGC00181005-01; 61950-59-2; [D-Trp8]-SOMATOSTATIN; SCHEMBL3046327

Indication

Disease Entry	ICD 11	Status	REF
Acromegaly	5A60.0	Approved	[1]
Carcinoid syndrome	5B10	Approved	[2]
Discovery agent	N.A.	Investigative	[3]

• Cross-matching ID:
  PubChem CID: 16129706
  ChEBI ID: CHEBI:64628
  CAS Number: CAS 38916-34-6
  TTD Drug ID: DMIOFQE

Molecule-Related Drug Atlas

Drug(s) Targeting Somatostatin receptor type 3 (SSTR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pasireotide	DMHM7JS	Cushing disease	5A70	Approved	[5]
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[7]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	DM7MZ2V	Discovery agent	N.A.	Investigative	[8]
Des-AA1,2,5,12,13-[D-Trp8]SRIF	DM1KJAE	Discovery agent	N.A.	Investigative	[6]
SRIF-28	DM0OM9L	Discovery agent	N.A.	Investigative	[9]
99mTc-MIP-1407	DMYPD5L	Neuroendocrine cancer	2B72.1	Investigative	[7]
Des-AA1,2,4,12,13-[D-Trp8]SRIF	DMMWDC5	Discovery agent	N.A.	Investigative	[6]
Cytotoxin Peptide Conjugate	DM7SVLZ	Discovery agent	N.A.	Investigative	[10]
Des-AA1,2,4,13-[D-Trp8]SRIF	DMR6Z2N	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Somatostatin receptor type 1 (SSTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pasireotide	DMHM7JS	Cushing disease	5A70	Approved	[11]
Lutetium Lu 177 dotatate	DMN1XVC	Neuroendocrine cancer	2B72.1	Approved	[12]
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[7]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	DM7MZ2V	Discovery agent	N.A.	Investigative	[8]
Des-AA1,2,5,12,13-[D-Trp8]SRIF	DM1KJAE	Discovery agent	N.A.	Investigative	[6]
SRIF-28	DM0OM9L	Discovery agent	N.A.	Investigative	[9]
99mTc-MIP-1407	DMYPD5L	Neuroendocrine cancer	2B72.1	Investigative	[7]
Des-AA1,2,4,12,13-[D-Trp8]SRIF	DMMWDC5	Discovery agent	N.A.	Investigative	[6]
Cytotoxin Peptide Conjugate	DM7SVLZ	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Opioid receptor mu (MOP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[13]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[14]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[15]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[16]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[17]
Alfentanil	DMVO0UB	Anaesthesia	9A78.6	Approved	[18]
Naloxegol	DML0B41	Opioid-induced constipation	DB32.1	Approved	[19]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[20]
Nalfurafine hcl	DMA9DHW	Uremic pruritus	EC90.10	Approved	[21]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[22]

Drug(s) Targeting Somatostatin receptor type 2 (SSTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pasireotide	DMHM7JS	Cushing disease	5A70	Approved	[23]
Octreotide	DMHIDCJ	Acromegaly	5A60.0	Approved	[24]
Lanreotide acetate	DMG6ZU4	Acromegaly	5A60.0	Approved	[25]
Ga-68-DOTATOC	DMZ0P95	Diagnostic imaging	N.A.	Approved	[26]
Copper dotatate Cu-64	DM26KR1	Diagnostic imaging	N.A.	Approved	[27]
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
Paltusotine	DM97IN2	Acromegaly	5A60.0	Phase 3	[28]
TBR-760	DMM5BVG	Pituitary adenoma	2F37.0	Phase 2	[29]
Re-188-P-2045	DM614BA	Lung cancer	2C25.0	Phase 1/2	[30]
PEN-221	DMMAUOK	Neuroendocrine cancer	2B72.1	Phase 1/2	[31]

Drug(s) Targeting Opioid receptor delta (OPRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Codeine	DMJX6ZG	Allergic rhinitis	CA08.0	Approved	[32]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[33]
Loperamide	DMOJZQ9	Diarrhea	ME05.1	Approved	[34]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[20]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[35]
Butorphanol	DM5KYPJ	Pain	MG30-MG3Z	Approved	[32]
Carfentanil	DM7ADGX	N. A.	N. A.	Phase 2	[36]
Met-enkephalin	DMSZFTP	Pain	MG30-MG3Z	Phase 2	[37]
AZD-2327	DM8FZOG	Anxiety disorder	6B00-6B0Z	Phase 2	[38]
ADL-5747	DMMUPTN	Pain	MG30-MG3Z	Phase 2	[39]

Drug(s) Targeting Somatostatin receptor type 4 (SSTR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
177Lu-DOTATATE	DMT8GVU	Hepatitis C virus infection	1E51.1	Phase 2	[40]
LY3556050	DMTW2XB	Chronic low-back pain	MG30	Phase 2	[41]
CNTX-0290	DMJPEVA	Chronic pain	MG30	Phase 1	[42]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[43]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	DM7MZ2V	Discovery agent	N.A.	Investigative	[8]
Des-AA1,2,5,12,13-[D-Trp8]SRIF	DM1KJAE	Discovery agent	N.A.	Investigative	[6]
SRIF-28	DM0OM9L	Discovery agent	N.A.	Investigative	[9]
99mTc-MIP-1407	DMYPD5L	Neuroendocrine cancer	2B72.1	Investigative	[44]
Des-AA1,2,4,12,13-[D-Trp8]SRIF	DMMWDC5	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Somatostatin receptor type 5 (SSTR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pasireotide	DMHM7JS	Cushing disease	5A70	Approved	[45]
ODT-8	DMBWO5T	N. A.	N. A.	Phase 3	[6]
FR-121196	DMNRUGA	Alzheimer disease	8A20	Terminated	[43]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF	DM7MZ2V	Discovery agent	N.A.	Investigative	[8]
Des-AA1,2,5,12,13-[D-Trp8]SRIF	DM1KJAE	Discovery agent	N.A.	Investigative	[6]
SRIF-28	DM0OM9L	Discovery agent	N.A.	Investigative	[9]
99mTc-MIP-1407	DMYPD5L	Neuroendocrine cancer	2B72.1	Investigative	[45]
Des-AA1,2,4,12,13-[D-Trp8]SRIF	DMMWDC5	Discovery agent	N.A.	Investigative	[6]
Cytotoxin Peptide Conjugate	DM7SVLZ	Discovery agent	N.A.	Investigative	[10]
Des-AA1,2,4,13-[D-Trp8]SRIF	DMR6Z2N	Discovery agent	N.A.	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor delta (OPRD1)	TT27RFC	OPRD_HUMAN	Inhibitor	[4]
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Inhibitor	[4]
Somatostatin receptor type 1 (SSTR1)	TTIND6G	SSR1_HUMAN	Inhibitor	[3]
Somatostatin receptor type 2 (SSTR2)	TTZ6T9E	SSR2_HUMAN	Inhibitor	[3]
Somatostatin receptor type 3 (SSTR3)	TTJX3UE	SSR3_HUMAN	Inhibitor	[3]
Somatostatin receptor type 4 (SSTR4)	TTAE1BR	SSR4_HUMAN	Inhibitor	[3]
Somatostatin receptor type 5 (SSTR5)	TT2BC4G	SSR5_HUMAN	Inhibitor	[3]

References

• [1] A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021 Feb;24(1):1-13.
• [2] Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018 Feb;25(1):22-35.
• [3] Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
• [4] Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357).
• [6] Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
• [7] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [8] Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
• [9] Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
• [10] An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355).
• [12] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [13] Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
• [14] Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
• [15] Clinical pipeline report, company report or official report of signaturerx.
• [16] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [17] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [18] Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
• [19] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [20] Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
• [21] Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
• [24] Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
• [25] Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
• [26] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [27] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [28] Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022 Apr;25(2):328-339.
• [29] TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
• [30] The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
• [31] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [32] Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
• [33] Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
• [34] Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
• [35] Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
• [36] Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
• [37] Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
• [38] Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
• [40] New Drug in Development Shows Improved Progression-Free Survival for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors
• [41] ClinicalTrials.gov (NCT04874636) Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain. U.S.National Institutes of Health.
• [42] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [43] Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34.
• [44] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 358).
• [45] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359).